Fundraising FoxHelicore Biopharma
Southbury, US · Founded 2020 · 5 known investors
Find your way into Helicore Biopharma
Sign up to see every warm intro you have to Helicore Biopharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Helicore Biopharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Helicore Bio develops long-acting antibody-peptide conjugate therapies for obesity and cardiometabolic disease, using proprietary GLP-1R agonist and amylin receptor agonist peptide libraries combined with a GIP ligand-binding antibody backbone. Its pipeline targets quarterly-dosed treatments, with a first-in-class GIP-binding antibody validated in a Phase 1 study.
Founders & leadership
Investors · 5
How we know: Longitude Capital's portfolio page · funding news · fiercebiotech.com · the VCSheet dataset · Not right? Tell us
How we know: OrbiMed's portfolio page · funding news · fiercebiotech.com · the VCSheet dataset · Not right? Tell us
How we know: fiercebiotech.com · Not right? Tell us
How we know: a partner's Signal profile · press coverage · Not right? Tell us
Also in the syndicate · 1
Funding
SEC filings, press & company announcements$2M disclosed across 1 of 3 rounds · 2020–2025
- Undisclosed amountseries AJan 2025 · 2 sources
OrbiMed (lead), Versant (lead), Longitude Capital, Versant Ventures, Wellington Management
Source ↗
▶$2MraisedApr 2020 · 1 investors · TelecommunicationsRule 506(b)
- Waters KelloggDirector
- Lucas B. TurnerDirector
- Joshua DotsonDirector
- Kevin RussExecutive Officer, Director
- Holger KoehlerDirector
- Charles BridgeDirector
- Offering amount
- $2M
- Amount sold
- $2M
- Minimum investment
- $2M
- First sale
- Apr 2020
- Incorporated
- Limited Liability Company, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Helicore Biopharma do?
- Helicore Bio develops long-acting antibody-peptide conjugate therapies for obesity and cardiometabolic disease, using proprietary GLP-1R agonist and amylin receptor agonist peptide libraries combined with a GIP ligand-binding antibody backbone. Its pipeline targets quarterly-dosed treatments, with a first-in-class GIP-binding antibody validated in a Phase 1 study.
- Who are Helicore Biopharma's investors?
- Helicore Biopharma's investors include Longitude Capital, OrbiMed, Wellington Management, Versant Ventures.
- How much funding has Helicore Biopharma raised?
- Helicore Biopharma has disclosed $2M raised across 1 of its 3 known rounds.
- Where is Helicore Biopharma headquartered?
- Helicore Biopharma is headquartered in Southbury, US.